The Pulmonary Fibrosis Foundation (PFF), the nation's leading pulmonary fibrosis (PF) research, education and advocacy ...

On Wednesday, Aileron Therapeutics Inc (NASDAQ; ALRN) revealed topline data from Cohort 2 of its Phase 1b trial of safety and ...

(RTTNews) - Aileron Therapeutics, Inc. (ALRN), Wednesday announced positive topline data from the cohort 2 of Phase 1b study evaluating LTI-03 in patients with idiopathic pulmonary fibrosis (IPF).

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...

Other causes of lung cancer are well known, like radon gas exposure, which happens to be fairly prevalent in Appalachia. It’s ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

Most people don’t enjoy getting shots for treatments or vaccines ... which was meant to model the lungs of people with cystic ...

Immunotherapy has dramatically improved the treatment outcomes of primary lung cancer; however, it sometimes causes a serious ...

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025On track to initiate U.S.

Last patient completed pivotal Phase 3 trial in CHB-associated liver fibrosis in the PRC with data expected in Q1 2025 On track to initiate U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis ...

Received tentative approval from the FDA for YUTREPIATM (treprostinil) inhalation powder for both pulmonary arterial hypertension (PAH) ...